Enjoy complimentary customisation on priority with our Enterprise License!
Cystitis is the inflammation of the bladder usually caused by a bladder infection. It is a common type of urinary tract infection. Women are more often affected by cystitis than men. UTI happens when bacteria enter the bladder or urethra and begin to multiply. It could also happen with naturally occurring bacteria in the body that become imbalanced. These bacteria lead to an infection and cause inflammation. Cystitis can either be acute or interstitial. Acute cystitis is a case of cystitis that occurs suddenly. Interstitial cystitis is a chronic or long-term case of cystitis that affects multiple layers of bladder tissue. Both acute and interstitial cystitis have a range of possible causes. Uncomplicated cystitis refers to a lower UTI in either men or nonpregnant women. The incidence of UTI is 12% in women based on self-reported annual incidences. Since UTI is estimated to occur with as a frequency as 0.7 infections per person per year. Fifty percent of females will have at least one UTI at some stage in their life. Consequently, with rising incidences of cystitis, the need for drug development for cystitis is expected to rise in the upcoming years.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for cystitis. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of cystitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
The intravesical route of administration (ROA) involves the application of the drug directly into the bladder, which will have a more direct effect on the target cells.
According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for cystitis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.